

## Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2018

Dec 05, 2018 | Press Releases

*Article 223-16 of general regulation of French Autorité des Marchés Financiers  
Lyon - France*

LYON, France, Dec. 05, 2018 (GLOBE NEWSWIRE) --

Listing markets:  
Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol: ERYP) &  
Nasdaq Global Select Market in the United-States (Symbol : ERYP)  
Website : [www.erytech.com](http://www.erytech.com)

Date	Total of shares composing the share capital	Total of brut <sup>(1)</sup> voting rights	Total of net <sup>(2)</sup> voting rights
December 31, 2017	17 937 559	19 545 443	19 542 943
January 1, 2018	17 940 035 <sup>(3)</sup>	19 543 919 <sup>(3)</sup>	19 541 419
February 28, 2018	17 940 035	19 546 219	19 543 719
March 31, 2018	17 940 035	19 546 221	19 543 721
April 30, 2018	17 940 035	19 554 221	19 551 721
May 31, 2018	17 940 035	19 543 991	19 541 491
June 30, 2018	17 940 035	19 525 991	19 523 491
July 31, 2018	17 940 035	19 525 991	19 523 491
August 31, 2018	17 940 035	19 525 991	19 523 491
September 30, 2018	17 940 035	19 525 741	19 523 241
October 31, 2018	17 940 035	19 525 741	19 523 241

- (1) *Gross voting rights number (or « theoretical » voting rights) is used as a basis for calculating the crossing of the threshold. In accordance with article 223-11 of general regulation of Autorité des Marchés Financiers, this number is calculated on the basis of all shares carrying the single and double voting rights, including shares without voting rights.*
- (2) *Without treasury shares*
- (3) *The number of shares and voting rights increased due to issuance of shares consequently to warrants exercises and or end of vesting periods of free shares which a Board of Director will take notice of in the future.*

**ERYTECH**  
**Eric Soyer**  
CFO & COO

**NewCap**  
**Mathilde Bohin/Louis-Victor Delouvrier**  
Investor relations  
**Nicolas Merigeau**  
Media relations

+33 (0)4 78 74 44 38  
[investors@erytech.com](mailto:investors@erytech.com)



Source: Erytech Pharma S.A.